
Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16
Published: April 17, 2025
Chimeric antigen receptor natural Killer (CAR-NK) cells therapy represents a next-generation immunotherapeutic approach following CAR-T therapy, offering inherent “off-the-shelf” compatibility and mitigated off-tumor toxicity. Despite these advantages, clinical translation remains constrained by poor in vivo persistence functional exhaustion immunosuppressive tumor microenvironments (TME). This review examines recent advancements synthetic biology aimed at enhancing the physiological characteristics of CAR-NK cells. By delineating synergy between NK toolkits, this work provides roadmap for developing therapies capable addressing solid challenges while maintaining favorable safety profiles.
Language: Английский